Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing - Archive ouverte HAL Access content directly
Journal Articles International Journal of Cancer Year : 2019

Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing

(1, 2) , (1, 2) , (3) , (1, 2) , (4) , (1, 2) , (5) , (6) , (7) , (2, 1) , (2, 1) , (2, 1) , (2, 1) , (2, 1) , (2, 1) , (2, 1) , (3) , (3) , (8) , (9) , (10) , (11) , (12, 13) , (14) , (15) , (16) , (17) , (18) , (19) , (20) , (21, 22) , (23) , (24) , (25) , (26) , (27) , (28) , (29) , (30) , (31) , (32) , (33, 34) , (35) , (36) , (37) , (38) , (39) , (40) , (41) , (42) , (43) , (44) , (45) , (46) , (47) , (48) , (49) , (1, 2) , (3) , (50) , (3) , (13, 51) , (1, 2) , (1, 2)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
Anne Fajac
  • Function : Author
Julie Tinat
  • Function : Author
  • PersonId : 928994
Hélène Dreyfus
  • Function : Author
  • PersonId : 912530
Capucine Delnatte
  • Function : Author
  • PersonId : 910040
Laurence Faivre
  • Function : Author
  • PersonId : 856301
Alain Lortholary
  • Function : Author
  • PersonId : 928991
Olivier Caron
  • Function : Author
Isabelle Coupier
  • Function : Author
  • PersonId : 907537
Anne Boland

Abstract

Pathogenic variants in BRCA1 and BRCA2 only explain the underlying genetic cause of about 10% of hereditary breast and ovarian cancer families. Because of cost-effectiveness, multigene panel testing is often performed even if the clinical utility of testing most of the genes remains questionable. The purpose of our study was to assess the contribution of rare, deleterious-predicted variants in DNA repair genes in familial breast cancer (BC) in a well-characterized and homogeneous population. We analyzed 113 DNA repair genes selected from either an exome sequencing or a candidate gene approach in the GENESIS study, which includes familial BC cases with no BRCA1 or BRCA2 mutation and having a sister with BC (N = 1,207), and general population controls (N = 1,199). Sequencing data were filtered for rare loss-of-function variants (LoF) and likely deleterious missense variants (MV). We confirmed associations between LoF and MV in PALB2, ATM and CHEK2 and BC occurrence. We also identified for the first time associations between FANCI, MAST1, POLH and RTEL1 and BC susceptibility. Unlike other associated genes, carriers of an ATM LoF had a significantly higher risk of developing BC than carriers of an ATM MV (ORLoF = 17.4 vs. ORMV = 1.6; p Het = 0.002). Hence, our approach allowed us to specify BC relative risks associated with deleterious-predicted variants in PALB2, ATM and CHEK2 and to add MAST1, POLH, RTEL1 and FANCI to the list of DNA repair genes possibly involved in BC susceptibility. We also highlight that different types of variants within the same gene can lead to different risk estimates.
Fichier principal
Vignette du fichier
Girard_et_al-2019-International_Journal_of_Cancer.pdf (834.22 Ko) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

inserm-02438452 , version 1 (14-01-2020)

Identifiers

Cite

Elodie Girard, Séverine Eon‐marchais, Robert E Olaso, Anne‐laure Renault, Francesca Damiola, et al.. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing. International Journal of Cancer, 2019, 144 (8), pp.1962-1974. ⟨10.1002/ijc.31921⟩. ⟨inserm-02438452⟩
662 View
114 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More